Market Research Report
Market Access Impact: Melanoma (EU5) 2018
|Published by||FirstWord||Product code||488062|
Delivery time: 1-2 business days
Please contact us using the inquiry form for pricing information.
|Market Access Impact: Melanoma (EU5) 2018|
|Published: February 1, 2018||Content info:||
Market barriers affect a fifth of melanoma prescriptions. Is your brand losing out?
In the EU5, market barriers affect a fifth of all melanoma prescriptions, giving the top brand a narrow lead over two rivals that are in 2nd and 3rd place. Find out how eliminating barriers would shake up the top and middle of the market, and help the last place brand double its share in Market Access Impact: Melanoma (EU5) .
Based on a survey of 150 oncologists and dermato-oncologists, the report covers 8 major therapies from Amgen, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, and Roche. Handy graphs and charts reveal which of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.
Insight into 8 Major Melanoma Drugs
Market Access Impact: Melanoma (EU5) explores key issues affecting Melanoma drug manufacturers. You'll learn:
How barriers affect market access:
How barriers affect your brand:
A Report Based on Expert Knowledge
We surveyed 150 medical oncologists and dermato-oncologists-30 from each EU5 country (France, Italy, Germany, Spain, UK)-chosen from the largest community of validated physicians in the world. All respondents have:
We conducted the survey between January 10-23, 2018.
Money Back Guarantee!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.